BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 24-Aug-2016

Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity rating (Surveillance) of the Company as "A1" along with a stable outlook based on audited financial statements up to December 31, 2015, bank liability position as on March 31, 2016 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

ORIONPHARM 10-May-2016

The Company has informed that the Board of Directors of the Company has decided, according to the Companies Act, 1994 and the BSEC Directive Dated April 27, 2016, to extend the Financial Year 2015 of the Company by an additional period of 6 months comprising to 18 months period ending on 30th June, 2016 instead of 31st December, 2015 in order to comply with the uniform income year from July to June as per provision of Section 9 of the Finance Act, 2015.

ORIONPHARM 01-Mar-2016

In response to a CSE query dated February 29, 2016, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike.

ORIONPHARM 01-Nov-2015

(Continuation news of ORIONPHARM): Consolidated NAV per share including revaluation surplus was Tk. 69.48 as of September 30, 2015 and Tk. 67.50 as of December 31, 2014, Consolidated NAV per share excluding revaluation surplus was Tk. 60.35 as of September 30, 2015 and Tk. 58.25 as of December 31, 2014.(end)

ORIONPHARM 01-Nov-2015

(Q3 Un-audited): Consolidated EPS was Tk. 0.73 for July- September, 2015 as against Tk. 0.77 for July- September., 2014; Consolidated EPS was Tk. 2.88 for January-September, 2015 as against Tk. 3.80 for January-September, 2014. Consolidated NOCFPS was Tk. 5.40 for January-September, 2015 as against Tk. 8.45 for January-September, 2014. (cont.)

ORIONPHARM 25-Oct-2015

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 29, 2015 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on September 30, 2015.

ORIONPHARM 30-Jul-2015

(Continuation news of ORIONPHARM-Q2): Consolidated NAV per share including revaluation surplus was Tk. 68.31 as of June 30, 2015 and Tk. 67.50 as of December 31, 2014, NAV per share excluding revaluation surplus was Tk. 61.68 as of June 30, 2015 and Tk. 58.25 as of December 31, 2014.(end)

ORIONPHARM 30-Jul-2015

(Q2 Un-audited): Consolidated EPS for April-June, 2015 was Tk. 0.74 as against Tk. 1.40 for April-June, 2014, Consolidated EPS for Jan-June, 2015 was Tk. 2.15 as against Tk. 3.03 for Jan-June, 2014. Consolidated NOCFPS was Tk. 4.32 for Jan-June, 2015 as against Tk. 6.81 for Jan-June, 2014. (cont.)

ORIONPHARM 21-Jun-2015

Credit Rating Agency of Bangladesh Limited (CRAB) has announced the entity rating (surveillance) of the Company as "A1" along with a stable outlook based on audited financial statements of the Company up to December 31, 2014; bank liability position as of May 31, 2015 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

ORIONPHARM 07-Jun-2015

In response to a CSE query dated June 01, 2015, the Company has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike.

Previous Next page